BioWorld MedTech

Jan. 13, 2016

J.P. Morgan Healthcare Conference 2016: Medtronic to return $5 billion of freed cash to shareholders

SAN FRANCISCO — As Medtronic plc (Dublin) approaches the anniversary of its blockbuster Covidien deal, which closed a year ago this month, the company is making strides to prove the $42.9 billion acquisition is paying off. Read More

J.P. Morgan Healthcare Conference 2016: Heartware suffers more heartache over MVAD, trial in limbo after thrombus events

Inside the Beltway: Califf breezes through Senate hearing for top job at the FDA

Company accused of lowering evidence bar: PDAC once again votes to recommend Probuphine implant

Silimed issues still not resolved: Sientra's new CEO updates physicians over crisis with Brazilian operations

Daily M&A: Smith & Nephew acquires BST-Cargel assets from Piramal Healthcare

Financings: Accuray closes $70M straight debt agreements with Cerberus

Patent Watch: Entac gets patent for technology to predict gastrointestinal impairment

World in Review: Polaris using DNAnexus for clinical omics

People in Places

product briefs

MDD's Oncology Extra

Today's news in brief

BioWorld

BioWorld briefs for July 16, 2026.

AI-generated illustration of a neuron with tau protein aggregation

AAIC 2026: Age of amyloid is being joined by time of tau

BioWorld

The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...

Celia trial: data strong, analysts skeptical

BioWorld

Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 14, 2026

Voyager’s gene therapy reduces tau levels in AD models

BioWorld Science

At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical efficacy data for VY-1706, a blood-brain...